Presence of t(14;18) positive cells in blood and bone marrow does not predict outcome in follicular lymphoma

Abstract

Follicular Lymphoma International Prognostic Index-FLIPI is an established clinical predictor for outcome in follicular lymphoma. The role of molecular abnormalities in blood and bone marrow of follicular lymphoma patients including t(14;18) is less clear. Seventy-five patients from a single institution diagnosed with follicular lymphoma between1999 and 2005 were included into the study. Diagnosis was based on lymph node biopsy in 62 cases (83%). Thirty-nine patients (52%) had G1 histological grade and 47 (63%) had entirely follicular growth pattern, as well as 9 patients (12%) had systemic symptoms and 33 (44%) were assigned to a good risk according to FLIPI. Median age of patients was 53 years. During a median observation time of 3 years 63 patients (84%) required initiating anti-lymphoma treatment. Seventy-five samples of peripheral blood and 65 samples of bone marrow were collected at the diagnosis. Bcl2 rearrangements including major breakpoint region and minor breakpoint cluster region were investigated using nested polymerase chain reaction technique. The primary end points of the study were time to first line lymphoma treatment and progression-free survival. Cells carrying t(14;18) were found in 31 cases (41%) including 29 samples of peripheral blood and 26 samples of bone marrow. Detection of t(14;18) in blood and bone marrow at diagnosis had no influence on clinical outcome. Age, follicular growth pattern systemic symptoms, and FLIPI score above 1 were predictive for initiation of the first lymphoma therapy. Follicular growth pattern, initial nodal involvement, serum LDH level, and FLIPI score above 1 were predictive for longer progression-free survival.

Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program

“…[5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24] However, a few studies failed to confirm this observation. [25][26][27][28] In particular, a recent report by van Oers et al 28 failed to demonstrate any benefit of achieving postinduction PCRnegative status. This study raised concerns regarding the predictive value of MRD detection in the context of rituximab-intensive therapeutic programs.…”

“…4 Considerable evidence indicates that the persistence of polymerase chain reaction (PCR)-detectable residual tumor cells in the bone marrow (BM) and, to a lesser extent, peripheral blood is an independent predictor of relapse in FL [5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24] ; nevertheless, a few studies have failed to confirm this observation. [25][26][27][28] Concerns about the value of minimal residual disease (MRD) detection as an effective prognostic tool have been raised, particularly when applied to The results of this study were the subject of an oral presentation at the 2012 American Society of Hematology annual meeting.…”

“…4 Considerable evidence indicates that the persistence of polymerase chain reaction (PCR)-detectable residual tumor cells in the bone marrow (BM) and, to a lesser extent, peripheral blood is an independent predictor of relapse in FL 5-24 ; nevertheless, a few studies have failed to confirm this observation. [25][26][27][28] Concerns about the value of minimal residual disease (MRD) detection as an effective prognostic tool have been raised, particularly when applied to The results of this study were the subject of an oral presentation at the 2012 American Society of Hematology annual meeting.The online version of this article contains a data supplement.The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734.…”

Population-based epidemiological data of follicular lymphoma in Poland: 15 years of observation

“…Moreover, particular genes polymorphisms might be associated with the elevated risk of lymphoma-specific death, lymphoma progression, or overall survival 30 . There are no extensive molecular and genetic studies for the Poland population; the results include only single-center FL studies with a limited number of cases that can not provide more in-depth epidemiological insight into FL etiopathogenesis 31 .…”

Follicular Lymphoma and Mantle Cell Lymphoma

“…However, the value of BCL2-IGH qPCR for monitoring levels of residual disease has been repeatedly questioned [88]. Similarly, the dim staining for surface Ig light chains has made MRD monitoring by flow cytometry more difficult than in other lymphoproliferative disorders.…”